Comparison of two automated commercial assays for routine detection of anti-hepatitis E Virus IgM antibodies in clinical samples
- PMID: 38394738
- DOI: 10.1016/j.diagmicrobio.2024.116226
Comparison of two automated commercial assays for routine detection of anti-hepatitis E Virus IgM antibodies in clinical samples
Abstract
Diagnosis of hepatitis E virus (HEV) infection relies first on detection of IgM antibodies (Ab), sometimes completed with HEV RNA detection. This study aimed to compare the performance of two automated anti-HEV IgM Ab assays. Correlation between Virclia® (Vircell) and Liaison® (Diasorin) assays was carried out on 178 routine clinical samples. Both assays were run on 67 samples from HEV RT-PCR (Altona) screened patients, and 52 Wantai® EIA (Euroimmun) tested samples. An excellent correlation was observed between both assays with an overall agreement of 96.6% (172/178), and a kappa coefficient at 0.93. In HEV RNA positive group (n=43), IgM detection rate was 93.3% (14/15) in immunocompetent patients, with both assays. In immunocompromised patients, detection rate was 75% (21/28) and 71.4% (20/28) using Virclia® and Liaison XL® assays, respectively. Virclia® and Liaison® anti-HEV IgM assays have similar performance for the detection of anti-HEV IgM Ab.
Keywords: Automated assays; Diagnosis; HEV; IgM antibodies.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest Virclia and Diasorin provided free kits for the evaluation. They have no role in the design and the interpretation of results.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
